

PATENT

#13

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Vogels et al

Serial No.: 09/332,803

Filed: June 14, 1999

For: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS TO BE USED IN

GENE TILERAPY

Examiner: D. Guzo

Group Art Unit: 1636

Attorney Docket No.: 4075US

Express Mail Mailing Label Number. <u>EL 740535688US</u>

NOTICE OF EXPRESS MAILING

Person making Denosir: Lane He F.

g/ro/01

Declaration

Commissioner for Patents Washington, D.C. 20231

Sir:

I, Dr. Domenico Valerio, declare that I am the President and Chief Executive Officer of Crucell Holland, B.V., successor in interest To IntroGene B. V. ("IntroGene"), and declare that:

- 1. I am informed and believe that IntroGene is the named assignee of U.S. patent application serial no. 09/332,803.
- 2.
- 3.



Serial No. 09/332,803

4. I am informed and believe that IntroGene made a deposit of a cell line of PGK-E1-Retinoblasts, known as "PER.C6", under number ECACC 96022940 under the provisions of the Budapest Treaty with the Centre for Applied Microbiology and Research Authority (European Collection of Animal Cell Cultures), Porton Down, Salisbury, Wiltshire SP4, OJG, United Kingdom, an International Depository Authority, in accordance with the Budapest Treaty.

5.

6. On behalf of IntroGene, 1 state that all restrictions upon public access to the deposit (except those specifically permitted by 37 C.F.R. § 1.808(b)) will be irrevocably removed upon the grant of a U.S. patent on the referenced U.S. patent application, and the deposit will be replaced if viable samples cannot be dispensed by the depository.

7.

8. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the U.S. Code and that such willful false statements may jeopardize the validity of the patent.

Q

10. Date: 2 July '01

Dr. Domenico Valerio